Sign In
Buy BLFS
$27.25
-0.240 (-0.87%)
At Close: Jun 03, 2026
BioLife Solutions, Inc. (BLFS) Reports Break-Even Earnings for Q2
06:21pm, Thursday, 07'th Aug 2025
BioLife Solutions, Inc. (BLFS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.06 per share a year ago.
BioLife Solutions Reports Second Quarter 2025 Financial Results
04:03pm, Thursday, 07'th Aug 2025
Cell Processing revenue of $23.0 million, up 28% over Q2 2024 GAAP gross margin of 62% and non-GAAP adjusted gross margin of 65% GAAP net loss of $15.8 million, inclusive of a non-cash $15.5 million
BioLife Solutions Makes Strategic Investment in Pluristyx
08:05am, Monday, 28'th Jul 2025
BOTHELL, Wash. , July 28, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") ma
BioLife Solutions to Report Second Quarter 2025 Financial Results and Business Update on August 7, 2025
04:05pm, Thursday, 24'th Jul 2025
BOTHELL, Wash. , July 24, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") ma
How Much Upside is Left in BioLife Solutions (BLFS)? Wall Street Analysts Think 41.72%
11:02am, Thursday, 05'th Jun 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 41.7% in BioLife Solutions (BLFS). While the effectiveness of this highly sought-after metric is questionable,
BioLife Solutions to Participate in Upcoming Investor Conferences in May and June 2025
08:03am, Wednesday, 14'th May 2025
BOTHELL, Wash. , May 14, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") mar
Can BioLife Solutions (BLFS) Climb 30.68% to Reach the Level Wall Street Analysts Expect?
11:01am, Tuesday, 13'th May 2025
The consensus price target hints at a 30.7% upside potential for BioLife Solutions (BLFS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings
BioLife Solutions, Inc. (BLFS) Q1 2025 Earnings Call Transcript
10:59pm, Thursday, 08'th May 2025
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Roderick de Greef - Chairman and Chief Exe
BioLife Solutions, Inc. (BLFS) Q1 Earnings and Revenues Beat Estimates
06:25pm, Thursday, 08'th May 2025
BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.19 per share a year a
BioLife Solutions Updates Earnings Call Information
04:32pm, Thursday, 08'th May 2025
BOTHELL, Wash. , May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell
BioLife Solutions Reports First Quarter 2025 Financial Results
04:03pm, Thursday, 08'th May 2025
Cell Processing revenue of $21.6 million, up 33% over Q1 2024 GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 mi
Stock Picks From Seeking Alpha's April 2025 New Analysts
08:00am, Tuesday, 06'th May 2025
In April, Seeking Alpha welcomed 20 new analysts. This article introduces them and showcases some of their top picks. Top picks include Palantir, Arch Capital Group, and Utah Medical Products, emphasi
BioLife Solutions to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
08:03am, Wednesday, 30'th Apr 2025
BOTHELL, Wash. , April 30, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") m
BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company
08:03am, Monday, 07'th Apr 2025
Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology Marks the second acquisition from Bioproduction Innovation Accelerator program BO
BioLife Solutions: A Steady Stock Lined Up For Success In A Booming Industry
04:43am, Sunday, 06'th Apr 2025
BioLife Solutions, an established biotech firm, is poised to benefit from the booming cell and gene therapy sector, projected to grow significantly by 2030. Despite recent negative EPS, BioLife has co
